샘플 요청 목록

 카트 문의
시장보고서
상품코드
1787225

세계의 신경통 치료 시장

Neuralgia Treatment
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 276 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 신경통 치료 시장은 2030년까지 32억 달러에 도달

2024년에 23억 달러로 추정되는 세계의 신경통 치료 시장은 2024-2030년에 CAGR 6.0%로 성장하며, 2030년에는 32억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 수술 기반의 치료는 CAGR 6.8%를 기록하며, 분석 기간 종료까지 23억 달러에 달할 것으로 예측됩니다. 약제 기반의 치료 분야의 성장률은 분석 기간 중 CAGR 3.8%로 추정됩니다.

미국 시장은 6억 1,850만 달러로 추정, 중국은 CAGR 9.6%로 성장 예측

미국의 신경통 치료 시장은 2024년에 6억 1,850만 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 6억 6,010만 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년의 CAGR은 9.6%입니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 2.9%와 5.9%로 예측됩니다. 유럽에서는 독일이 CAGR 3.9%로 성장할 것으로 예측됩니다.

세계 신경통 치료제 시장 - 주요 동향 및 촉진요인 정리

신경통 치료가 통증 관리에서 주목받는 이유는?

신경통은 강렬하고 날카로우며 종종 만성적인 신경통을 특징으로 하는 질환으로, 환자의 삶의 질을 떨어뜨리기 때문에 통증 관리의 주요 초점이 되고 있습니다. 신경통은 신경 손상, 감염, 염증 또는 당뇨병, 다발성 경화증, 대상포진 후 합병증과 같은 기저질환으로 인해 발생할 수 있습니다. 신경통의 일반적인 유형에는 삼차신경통, 후두신경통, 대상포진 후 신경통 등이 있으며, 각 유형에 맞는 치료법이 필요합니다. 비스테로이드성 항염증약(NSAIDs)나 오피오이드와 같은 전통적인 진통제는 진통 효과가 제한적인 경우가 많아 항경련제, 항우울제, 신경차단제, 신경조절요법 등 보다 효과적인 치료법에 대한 수요가 증가하고 있습니다. 현재 신경통 치료의 발전에는 미세혈관감압술(MVD), 고주파소작술(RFA)과 같은 최소침습적 수술적 중재와 척수자극술(SCS), 표적약물전달시스템과 같은 새로운 기술들이 포함됩니다. 만성 통증 질환의 유병률이 전 세계에서 증가하는 가운데, 신경통 치료 시장에서는 장기적인 통증 완화 및 환자 예후 개선을 위한 혁신적인 통증 관리 솔루션에 대한 투자가 증가하고 있습니다.

효과적인 신경통 치료를 방해하는 요인은 무엇인가?

통증 관리의 발전에도 불구하고 신경통의 효과적인 치료를 방해하는 몇 가지 문제가 있습니다. 주요 우려 사항 중 하나는 신경통의 증상이 다른 신경병증성 통증 질환과 중복될 수 있으며, 정확한 진단이 어려워 오진이나 치료 지연으로 이어질 수 있다는 점입니다. 또한 신경통은 복잡하므로 환자마다 치료 효과가 크게 달라 시행착오가 필요하며, 통증이 오래 지속될 수 있습니다. 또한 오피오이드 등 기존 신경통 치료제의 경우 의존성, 중독성, 부작용의 위험이 있으며, 보다 안전한 대체약물 개발이 필요합니다. 또한 신경조절 기기나 외과적 개입을 포함한 고급 치료법은 고가의 비용이 들기 때문에 특히 개발도상국에서는 접근성이 떨어집니다. 또 다른 큰 과제는 통증 관리에 대한 인식과 전문 통증 관리 센터의 부족으로 많은 환자들에게 과소 진단과 불충분한 치료로 이어지고 있다는 점입니다. 또한 새로운 통증 관리 약물 및 기기에 대한 규제 장벽은 시장 진입을 지연시키고 혁신적인 신경통 치료에 대한 접근성을 제한하고 있습니다. 이러한 문제를 해결하기 위해서는 연구에 대한 투자 확대, 의료진에 대한 의료 교육 강화, 근거에 기반한 저렴한 통증 관리 요법에 대한 접근성 개선이 필요합니다.

혁신은 신경통 치료를 어떻게 변화시키고 있는가?

신경통 치료 시장은 통증 완화, 부작용 감소, 환자 예후 개선을 목표로 하는 획기적인 기술 혁신을 목격하고 있습니다. 가장 유망 발전 중 하나는 경피적 전기 신경 자극(TENS), 척수 자극(SCS), 후근신경절(DRG) 자극과 같은 신경조절 요법을 사용하여 신경 수준에서 통증 신호를 조절하고 장기적인 완화를 가져옵니다. 또 다른 큰 발전은 통증 치료제를 환부의 신경 부위에 직접 방출하여 전신적인 부작용을 감소시키는 표적 약물전달 시스템의 출현입니다. 유전자 치료와 재생의료 역시 줄기세포 치료와 신경성장인자가 손상된 신경을 복구하고 정상 기능을 회복할 수 있는 가능성을 탐색하는 연구로 주목받고 있습니다. 또한 라디오파 소작술(RFA)과 냉동 신경 용해술의 발전으로 큰 수술 없이 통증 경로를 파괴하여 장기적인 통증 완화를 가능하게 하는 최소 침습적 치료법이 제공되고 있습니다. 인공지능(AI)과 머신러닝도 통증 관리에 접목되고 있으며, 의사가 환자별 통증 패턴과 반응 데이터에 따라 치료 계획을 개별화할 수 있도록 돕고 있습니다. 이러한 기술 혁신이 계속 발전함에 따라 보다 효과적이고 덜 침습적이며 환자 중심의 솔루션으로 전환되어 지속적인 통증 완화와 삶의 질을 향상시키는 방향으로 나아가고 있습니다.

신경통 치료제 시장의 성장 원동력은?

신경통 치료 시장의 성장은 신경병성 통증 질환의 유병률 증가, 만성 통증 관리에 대한 인식 증가, 통증 완화 기술의 발전 등 여러 요인에 의해 주도되고 있습니다. 세계 인구의 고령화는 대상포진, 당뇨병 관련 신경 손상, 퇴행성 신경질환 등의 증상을 유발하기 쉽고, 신경통의 발생률 증가에 기여하고 있습니다. 또한 비오피오이드 계열의 통증 관리 솔루션에 대한 관심이 높아지면서 신경조절, 표적 약물전달, 재생의료 등 대체요법에 대한 수요가 증가하고 있습니다. 통증 관리 클리닉과 전문 의료시설의 개발은 특히 선진 지역에서 고급 신경통 치료에 대한 접근성을 향상시키고 있습니다. 또한 연구개발에 대한 투자 증가로 생물제제, AI 지원 치료 계획 등 새로운 치료법의 도입이 가속화되고 있습니다. 만성 통증 관리를 촉진하기 위한 정부의 구상과 혁신적인 치료법을 지원하는 상환 정책은 시장 성장을 더욱 촉진하고 있습니다. 신경통이 공중보건의 중요한 관심사로 남아있는 가운데, 효과적이고 접근하기 쉬운 첨단 치료 옵션에 대한 수요가 증가하면서 통증 관리의 미래가 형성되고 전 세계 수백만 명의 환자들의 삶이 개선될 것으로 예측됩니다.

부문

치료 유형(수술 기반 치료, 약물 기반 치료), 최종사용자(병원·진료소 최종사용자, 외래 수술 센터 최종사용자, 기타 최종사용자)

조사 대상 기업의 예

  • Abbott Laboratories
  • Allergan plc
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bayer AG
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company, Limited
  • Dr. Reddy's Laboratories
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc(GSK)
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.

AI 통합

Global Industry Analysts는 유효한 전문가 컨텐츠와 AI 툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 일반적인 LLM나 업계별 SLM 쿼리에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 대량 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.08.18

Global Neuralgia Treatment Market to Reach US$3.2 Billion by 2030

The global market for Neuralgia Treatment estimated at US$2.3 Billion in the year 2024, is expected to reach US$3.2 Billion by 2030, growing at a CAGR of 6.0% over the analysis period 2024-2030. Surgery-based Treatment, one of the segments analyzed in the report, is expected to record a 6.8% CAGR and reach US$2.3 Billion by the end of the analysis period. Growth in the Drug-based Treatment segment is estimated at 3.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$618.5 Million While China is Forecast to Grow at 9.6% CAGR

The Neuralgia Treatment market in the U.S. is estimated at US$618.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$660.1 Million by the year 2030 trailing a CAGR of 9.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.9% and 5.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.9% CAGR.

Global Neuralgia Treatment Market - Key Trends & Drivers Summarized

Why Is Neuralgia Treatment Becoming a Key Focus in Pain Management?

Neuralgia, a condition characterized by severe, sharp, and often chronic nerve pain, has become a major area of focus in pain management due to its debilitating impact on patients' quality of life. Neuralgia can result from nerve damage, infections, inflammation, or underlying conditions such as diabetes, multiple sclerosis, and postherpetic complications from shingles. Common types of neuralgia include trigeminal neuralgia, occipital neuralgia, and postherpetic neuralgia, each requiring tailored treatment approaches. Traditional pain relief methods such as nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids often provide limited relief, leading to increased demand for more effective treatments, including anticonvulsants, antidepressants, nerve blocks, and neuromodulation therapies. Advancements in neuralgia treatment now include minimally invasive surgical interventions such as microvascular decompression (MVD) and radiofrequency ablation (RFA), as well as emerging techniques like spinal cord stimulation (SCS) and targeted drug delivery systems. As the prevalence of chronic pain conditions rises globally, the neuralgia treatment market is witnessing increased investment in innovative pain management solutions that offer long-term relief and improved patient outcomes.

What Challenges Are Hindering Effective Neuralgia Treatment?

Despite advancements in pain management, several challenges continue to hinder the effective treatment of neuralgia. One of the primary concerns is the difficulty in accurately diagnosing neuralgia, as its symptoms can overlap with other neuropathic pain disorders, leading to misdiagnosis or delayed treatment. The complexity of nerve pain also means that treatment effectiveness varies significantly from patient to patient, requiring a trial-and-error approach that can prolong suffering. Additionally, many conventional neuralgia treatments, such as opioids, come with risks of dependency, addiction, and adverse side effects, necessitating the development of safer alternatives. High costs associated with advanced treatment options, including neuromodulation devices and surgical interventions, also limit accessibility, particularly in developing regions. Another major challenge is the lack of awareness and specialized pain management centers, leading to underdiagnosis and inadequate treatment for many patients. Furthermore, regulatory hurdles for novel pain management drugs and devices can delay market entry, restricting access to innovative neuralgia treatments. Addressing these challenges requires greater investment in research, enhanced medical training for healthcare providers, and improved access to affordable, evidence-based pain management therapies.

How Are Innovations Transforming Neuralgia Treatment?

The neuralgia treatment market is witnessing groundbreaking innovations aimed at improving pain relief, reducing side effects, and enhancing patient outcomes. One of the most promising advancements is the use of neuromodulation therapies, including transcutaneous electrical nerve stimulation (TENS), spinal cord stimulation (SCS), and dorsal root ganglion (DRG) stimulation, which modulate pain signals at the nerve level, providing long-term relief. Another major development is the emergence of targeted drug delivery systems that release pain medications directly at the affected nerve sites, reducing systemic side effects. Gene therapy and regenerative medicine are also gaining traction, with research exploring the potential of stem cell therapy and nerve growth factors to repair damaged nerves and restore normal function. Additionally, advancements in radiofrequency ablation (RFA) and cryoneurolysis are offering minimally invasive options for long-lasting pain relief by disrupting pain pathways without the need for extensive surgery. Artificial intelligence (AI) and machine learning are also being integrated into pain management, helping doctors personalize treatment plans based on patient-specific pain patterns and response data. As these innovations continue to evolve, the landscape of neuralgia treatment is shifting towards more effective, less invasive, and patient-centric solutions that offer lasting pain relief and improved quality of life.

What Is Driving the Growth of the Neuralgia Treatment Market?

The growth in the neuralgia treatment market is driven by several factors, including the rising prevalence of neuropathic pain disorders, increasing awareness of chronic pain management, and advancements in pain relief technologies. The aging global population, which is more prone to conditions such as shingles, diabetes-related nerve damage, and degenerative neurological diseases, is contributing to the rising incidence of neuralgia. Additionally, the growing emphasis on non-opioid pain management solutions is fueling the demand for alternative therapies, including neuromodulation, targeted drug delivery, and regenerative medicine. The expansion of pain management clinics and specialized healthcare facilities is also improving access to advanced neuralgia treatments, particularly in developed regions. Furthermore, increasing investments in research and development are accelerating the introduction of novel therapies, including biologics and AI-assisted treatment plans. Government initiatives promoting chronic pain management and reimbursement policies supporting innovative treatments are further boosting market growth. As neuralgia continues to be a significant public health concern, the demand for advanced, effective, and accessible treatment options is expected to rise, shaping the future of pain management and improving the lives of millions of affected individuals worldwide.

SCOPE OF STUDY:

The report analyzes the Neuralgia Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment Type (Surgery-based Treatment, Drug-based Treatment); End-Use (Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • Abbott Laboratories
  • Allergan plc
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bayer AG
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company, Limited
  • Dr. Reddy's Laboratories
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc (GSK)
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Neuralgia Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Neuropathic Disorders Propels Demand for Neuralgia Treatment Solutions
    • Increasing Geriatric Population Base Strengthens Business Case for Long-Term Neuralgia Management
    • Growing Awareness Around Chronic Pain Conditions Drives Adoption of Early Intervention Therapies
    • Technological Advancements in Nerve Stimulation Devices Expand Addressable Market Opportunity
    • Emergence of Minimally Invasive Procedures Spurs Growth in Interventional Pain Management
    • Integration of AI and Predictive Analytics in Pain Diagnosis Enhances Precision and Supports Market Expansion
    • Increasing Availability of Targeted Drug Delivery Systems Drives Demand for Personalized Treatment
    • Shift Towards Multimodal Pain Therapy Approaches Drives Adoption of Complementary Treatments
    • Expansion of Telemedicine and Remote Care Solutions Accelerates Access to Neuralgia Treatment
    • Rising Investment in Pain Research and Innovation Pipelines Fuels Development of Next-Gen Therapeutics
    • Favorable Reimbursement Policies in Developed Economies Sustain Growth Momentum Across Key Markets
    • Escalating Use of Cannabinoid-Based Therapies Throws the Spotlight on Alternative Pain Management Modalities
    • Strong Pipeline of Biologics and Monoclonal Antibodies Expands Future Treatment Horizons
    • Increasing Regulatory Scrutiny on Opioid Usage Creates Opportunities for Safer Treatment Alternatives
    • Growing Collaboration Between Pharma and MedTech Players Spurs Innovation in Neurostimulation Technologies
    • Expansion of Pain Clinics and Specialty Care Centers Enhances Market Penetration in Emerging Regions
    • Rising Incidence of Diabetic Neuropathy and Post-Herpetic Neuralgia Drives Chronic Pain Treatment Demand
    • Increased Focus on Patient-Centric Care Models Strengthens Business Case for Home-Based Therapies
    • Regulatory Push for Non-Addictive Pain Therapies Drives Innovation in Drug Development Pipelines
    • Growth in Wearable and Implantable Pain Modulation Devices Drives Demand for Tech-Enabled Solutions
    • Adoption of Real-World Evidence (RWE) in Clinical Decision Making Enhances Market Credibility and Adoption
    • Government-Led Public Health Initiatives and Funding Support Expand Market Access in Underserved Regions
    • Surge in Mental Health Comorbidities with Chronic Pain Disorders Spurs Holistic Treatment Approaches
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Neuralgia Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Neuralgia Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Neuralgia Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Neuralgia Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Surgery-based Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Surgery-based Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Surgery-based Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Drug-based Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Drug-based Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Drug-based Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hospital & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hospital & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Hospital & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Ambulatory Surgery Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Neuralgia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: USA 15-Year Perspective for Neuralgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery-based Treatment and Drug-based Treatment for the Years 2015, 2025 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: USA 15-Year Perspective for Neuralgia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: Canada 15-Year Perspective for Neuralgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery-based Treatment and Drug-based Treatment for the Years 2015, 2025 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: Canada 15-Year Perspective for Neuralgia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • Neuralgia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Japan 15-Year Perspective for Neuralgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery-based Treatment and Drug-based Treatment for the Years 2015, 2025 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Japan 15-Year Perspective for Neuralgia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • Neuralgia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: China 15-Year Perspective for Neuralgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery-based Treatment and Drug-based Treatment for the Years 2015, 2025 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: China 15-Year Perspective for Neuralgia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • Neuralgia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Neuralgia Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Neuralgia Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Europe 15-Year Perspective for Neuralgia Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Europe 15-Year Perspective for Neuralgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery-based Treatment and Drug-based Treatment for the Years 2015, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Neuralgia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • FRANCE
    • Neuralgia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: France 15-Year Perspective for Neuralgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery-based Treatment and Drug-based Treatment for the Years 2015, 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: France 15-Year Perspective for Neuralgia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • Neuralgia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Germany 15-Year Perspective for Neuralgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery-based Treatment and Drug-based Treatment for the Years 2015, 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Germany 15-Year Perspective for Neuralgia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Italy 15-Year Perspective for Neuralgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery-based Treatment and Drug-based Treatment for the Years 2015, 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Italy 15-Year Perspective for Neuralgia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Neuralgia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: UK 15-Year Perspective for Neuralgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery-based Treatment and Drug-based Treatment for the Years 2015, 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: UK 15-Year Perspective for Neuralgia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Spain 15-Year Perspective for Neuralgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery-based Treatment and Drug-based Treatment for the Years 2015, 2025 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Spain 15-Year Perspective for Neuralgia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Russia 15-Year Perspective for Neuralgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery-based Treatment and Drug-based Treatment for the Years 2015, 2025 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Russia 15-Year Perspective for Neuralgia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 15-Year Perspective for Neuralgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery-based Treatment and Drug-based Treatment for the Years 2015, 2025 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 15-Year Perspective for Neuralgia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Neuralgia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Neuralgia Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Neuralgia Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 15-Year Perspective for Neuralgia Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 15-Year Perspective for Neuralgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery-based Treatment and Drug-based Treatment for the Years 2015, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Neuralgia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Neuralgia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Australia 15-Year Perspective for Neuralgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery-based Treatment and Drug-based Treatment for the Years 2015, 2025 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Australia 15-Year Perspective for Neuralgia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • INDIA
    • Neuralgia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: India 15-Year Perspective for Neuralgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery-based Treatment and Drug-based Treatment for the Years 2015, 2025 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: India 15-Year Perspective for Neuralgia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: South Korea 15-Year Perspective for Neuralgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery-based Treatment and Drug-based Treatment for the Years 2015, 2025 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: South Korea 15-Year Perspective for Neuralgia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 15-Year Perspective for Neuralgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery-based Treatment and Drug-based Treatment for the Years 2015, 2025 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 15-Year Perspective for Neuralgia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Neuralgia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Neuralgia Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Neuralgia Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Latin America 15-Year Perspective for Neuralgia Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Latin America 15-Year Perspective for Neuralgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery-based Treatment and Drug-based Treatment for the Years 2015, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Neuralgia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Argentina 15-Year Perspective for Neuralgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery-based Treatment and Drug-based Treatment for the Years 2015, 2025 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Argentina 15-Year Perspective for Neuralgia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Brazil 15-Year Perspective for Neuralgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery-based Treatment and Drug-based Treatment for the Years 2015, 2025 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Brazil 15-Year Perspective for Neuralgia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Mexico 15-Year Perspective for Neuralgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery-based Treatment and Drug-based Treatment for the Years 2015, 2025 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Mexico 15-Year Perspective for Neuralgia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 15-Year Perspective for Neuralgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery-based Treatment and Drug-based Treatment for the Years 2015, 2025 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 15-Year Perspective for Neuralgia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Neuralgia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Neuralgia Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Neuralgia Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Middle East 15-Year Perspective for Neuralgia Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Middle East 15-Year Perspective for Neuralgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery-based Treatment and Drug-based Treatment for the Years 2015, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Neuralgia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Iran 15-Year Perspective for Neuralgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery-based Treatment and Drug-based Treatment for the Years 2015, 2025 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Iran 15-Year Perspective for Neuralgia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Israel 15-Year Perspective for Neuralgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery-based Treatment and Drug-based Treatment for the Years 2015, 2025 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Israel 15-Year Perspective for Neuralgia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 15-Year Perspective for Neuralgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery-based Treatment and Drug-based Treatment for the Years 2015, 2025 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 15-Year Perspective for Neuralgia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: UAE 15-Year Perspective for Neuralgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery-based Treatment and Drug-based Treatment for the Years 2015, 2025 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: UAE 15-Year Perspective for Neuralgia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 15-Year Perspective for Neuralgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery-based Treatment and Drug-based Treatment for the Years 2015, 2025 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 15-Year Perspective for Neuralgia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • AFRICA
    • Neuralgia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Africa 15-Year Perspective for Neuralgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery-based Treatment and Drug-based Treatment for the Years 2015, 2025 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Africa 15-Year Perspective for Neuralgia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제